- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the first quarter of 2013.
The revenue recorded by NANOBIOTIX during the first quarter of 2013 corresponds to the upfront payment (pro-rata share for such quarter) received by the Company from Taiwan-based PharmaEngine, within the framework of the licensing contract. NANOBIOTIX signed the licensing contract with PharmaEngine in August 2012, for the development and marketing of its lead product, NBTXR3 in the Asia-Pacific region. The upfront payment totaled €810,640 and is apportioned using the straight-line method between the date the contract was signed and the scheduled marketing launch in the region i.e. approximately 5 years. The amount is in line with the Company's strategy, focused on the development and marketing of NBTXR3.
NANOBIOTIX is focusing its efforts to progress clinical development of NBTXR3. The product is undergoing phase I trials in patients with advanced Soft Tissue Sarcoma (STS) at the Institut Gustave Roussy, France. NANOBIOTIX published positive interim results regarding the safety of NBTXR3 in the first group of patients in November 2012. This is an encouraging milestone in the clinical validation process of NBTXR3.
NANOBIOTIX plans to progress clinical trials of NBTXR3, and will initiate a study in head and neck cancer patients later in 2013.
The timing and progress of the clinical development of NBTXR3 are in line with the Company's expectations and original plan at IPO.
Nanobiotix will present the therapeutic approach NanoXray and NBTXR3 clinical data to a group of oncologists and radiation oncologists. The scientific meeting will be held on June 1st 2013 in Chicago, USA.
Next financial press release: revenue for the 2nd quarter of 2013, on 12 July 2013
Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product, NBTXR3 based on NanoXray, is currently under clinical development for soft tissue sarcoma. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The Company is based in Paris, France.
Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).
For more information, please click here
CEO and Co-founder
Tel: +33 (0)1 40 26 07 55
Press Relations (Europe except France)
Melanie Toyne Sewell / Anastasios Koutsos / Donia Al Saffar
+44 (0)207 457 2020
Financial communication and Investor relations
Louis-Victor Delouvrier / Emmanuel Huynh
Tel: +33 (0)1 44 71 98 53
Annie-Florence Loyer / Nadège Le Lezec
Tel: +33 (0)1 53 63 27 27
Copyright © NanobiotixIf you have a comment, please Contact us.
|Related News Press|
News and information
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
Aspen Aerogels to Webcast 2015 Annual Meeting of Stockholders June 11th, 2015
Industrial Nanotech, Inc. Provides Update June 8th, 2015